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We report here on the synthesis of a series of mono- and dinuclear gold(I) complexes exhibiting 
sulfonated bis(NHC) ligands and novel hydroxylated mono(NHC) Au(I) compounds, which 
were also examined for their biological activities. Initial cell viability assays show strong 
antiproliferative activities of the hydroxylated mono(NHC) gold compounds (8 > 9 > 10) 
against 2008 human ovarian cancer cells even after 1 h incubation. In order to gain insight into 
the mechanism of biological action of the gold compounds, their effect on the pivotal cellular 
target seleno-enzyme thioredoxin reductase (TrxR), involved in the maintenance of the 
intracellular redox balance, was investigated in-depth. The compounds’ inhibitory effects on 
TrxR and glutathione reductase (GR) were studied comparatively, using either the pure proteins 
or cancer cell extracts. The results show strong and selective inhibitory effect of TrxR, 
specifically for the hydroxyl-functionalized NHC gold(I) complexes (8 - 10). Valuable 
information on the gold compounds’ molecular reactivity with TRxR was gained using the 
BIAM (biotin-conjugated iodoacetamide) assay and performing competition experiments by 
mass spectrometry (MS). In good agreement, both techniques suggest binding affinity of the 
mono-NHC Au(I) complexes towards selenols and thiols. Notably, for the first time, bis-
carbene formation from mono-carbenes in buffered solution could be observed by MS, which 
may provide new insights into the speciation mechanisms of bioactive Au(I) NCH complexes. 
Furthermore, the compounds’ interactions with another relevant in cellulo target, namely 
telomeric G-quadruplex DNA - a higher-order DNA structure playing key roles in telomere 
function - was investigated by means of FRET melting assays. The lack of interactions with 
this type of nucleic acid secondary structure support the idea of selective targeting of the 




Triggered by the success of cisplatin, metal-based anticancer therapy has immensely progressed 
in the scientific and clinical community over the last decades.1,2 Early observations that cisplatin 
treatment may lead to drug-resistance3 and is often associated with severe side effects (e.g. 
nephrotoxicity, neurotoxicity, ototoxicity)4,5 fostered the development of different cytotoxic 
Pt(II) and Pt(IV) derivatives (e.g. carboplatin, oxaliplatin, satraplatin),6–8 as well as of numerous 
antiproliferative agents based on other metals such as Ru9, Rh10, Cu11 and Ag12. As a 
consequence, over the last years structure-activity relationships (SAR) of a plethora of metal-
based compounds have been established, offering a useful perspective on the rational design of 
future metallodrugs.13–18 
Notably, gold-based compounds have been successfully tested for their anticancer effects in 
vitro and in vivo.19–22 Among them, auranofin ([2,3,4,6-tetra-o-acetyl-1-thio-β-ᴅ-
glucopyranosato-S-(triethyl-phosphine)Au(I)]), Ridaura®) - a linear mixed thiolato/phosphine 
Au(I) drug (Figure 1) originally utilized to treat rheumatoid arthritis - was recently repurposed 
for its anticancer properties and is currently undergoing evaluation in three distinct clinical trials 
in US.23,24 To a lesser extent, gold compounds have also been evaluated as antimicrobial25, anti-
malarial26 and anti-HIV27 agents. Despite their apparently favorable biological properties, 
coordination Au(I) complexes are subjected to extensive reactivity in physiological conditions, 
including ligand exchange reactions and reduction to colloidal gold. In this context, 
organometallic chemistry offers a convenient way for the stabilization of the Au(I) center and 
“fine-tuning” of the complexes’ physiochemical properties via the establishment of direct 
metal-carbon bonds. 
Within this framework, in the last decade, N-heterocyclic carbene ligands (NHCs), with 
chemical properties that resemble phosphine ligands,28 became of interest for medicinal 
applications, and since then, the research on organometallic Au(I) NHC complexes as potential 
antiproliferative agents increased strongly. 29,30 
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Concerning the possible mechanisms of biological action, a considerable amount of studies 
outline gold-mediated apoptosis related to the inhibition of specific intracellular proteins and 
enzymes.19,20,22,31,32 Among these, a prominent representative is the zinc-finger protein 
poly(adenosine diphosphate (ADP)-ribose) polymerase 1 (PARP-1) which can be efficiently 
inhibited by certain Au(III) and Au(I) compounds.33,34 Moreover, since their discovery as 
antiproliferative agents, various experiments on cancer cells revealed a variety of effects of 
Au(I) NHCs on cellular metabolism, including high increase of ROS formation and reduced 
mitochondrial activity, finally resulting in apoptotic cell death. Notably, most of these effects 
could be attributed to the strong and selective inhibition of the seleno-enzyme thioredoxin 
reductase (TrxR) by Au(I) NHC complexes.33,35 
Thioredoxin reductases are homodimeric flavoproteins catalysing the NADPH-dependent 
reduction of thioredoxin (Trx), which is the major protein disulfide reductase in cells.36 
Mammalian TrxRs possess a conserved -Cys-Val-Asn-Val-Gly-Cys- catalytic site, which is 
also found in human glutathione reductase (GR), located in the FAD-binding domain of the 
enzyme, and a NADPH binding site. In addition, TrxRs contain a selenocysteine (Sec) residue 
at the C-terminal active site that is crucial for catalysis37 and that distinguishes them from GR. 
The thioredoxin system regulates crucial cell functions such as viability and proliferation.38 
Indeed, both TrxR and Trx appear overexpressed in certain cancer types,39,40 leading to the 
assumption that the thioredoxin system exerts a crucial role in tumor onset and progression, and 
that could be used as a pharmacological target.41,42  
It is also worth mentioning that recently the biscarbene cationic complex [Au(9-methylcaffein-
8-ylidene)2]
+ (AuTMX2, Figure 1) was reported to be a selective binder of telomeric G-
quadruplexes (G4) by FRET DNA melting assays43, and the two caffeine ligands (guanine 
analogues) stabilizing the Au(I) centre were shown to associate to guanine moieties in G4 via 
-stacking interactions44.  G4s are peculiar nucleic acid architectures adopted by guanine-rich 
DNA and RNA sequences, whose stability originates in the stacking of contiguous G-quartets 
 5 
(a planar and cyclic K+-promoted association of four guanines in a Hoogsteen hydrogen-
bonding arrangement). Currently, G-quadruplexes are intensively studied, because they are 
suspected to play important roles in key cellular events: being found in eukaryotic telomeres 
and in promoter regions of identified oncogenes. Their stabilization by selective small 
molecules is thus currently investigated as a mean to control key cellular events and as a novel 
anticancer strategy.45 
In the past few years, the number of studies on water-soluble and hydrophilic metal complexes 
has markedly increased to achieve novel anticancer agents. Although certain lipophilicity is 
crucial to cross (cancer) cell membranes, the hydrophilic character of a species is significant 
for in vitro investigations and efficient in vivo administrations correlating with enhanced 
bioavailability under physiological conditions. Therefore, studies on different metals, including 
Ru(II)9,46–49, Pt(II)50,51, Ag(I)52 and Au(I, III)50,53–58, coordinated to water-soluble phosphine 
ligands, e.g. 1,3,5-triaza-7-phosphaadamantane (PTA), 3,7-diacetyl-1,3,7-triaza-5-
phosphabicyclo[3.3.1]nonane (DAPTA) and 1,4,7-triaza-9-phosphatricyclo[5.3.2.1]tridecane 
(CAP), or attached to appropriately functionalized N-heterocyclic carbene ligands, have shown 
promising cytotoxic activity. In this context Santini et al. have recently reported the synthesis 
of NHC ligands functionalized with hydrophilic groups such as esters or amides, which show 
moderate antiproliferative effects along with TrxR inhibition in the nanomolar range.59 
In this work, the synthesis and characterization of a series of hydrophilic N-heterocyclic carbene 
ligands functionalized with sulfonate and hydroxyl groups and their corresponding 
mononuclear Ag(I) and Au(I) complexes (Figure 1) is presented. In order to investigate the 
effect of multinuclearity on the biological activity, a dinuclear bis(NHC) Au(I) complex was 
added to the series. The Au(I) NHC compounds were tested as potential anticancer agents 
against ovarian cancer cell line 2008 and thoroughly investigated for their binding behaviour 
towards TrxR by various biochemical assays and mass spectrometry. Furthermore, the 
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compounds’ ability to induce ROS formation, as well as their potential to target G-quadruplex-
DNA was investigated. 
 
Figure 1. Structures of auranofin, G4-targeting AuTMX2 and of the hydrophilic NHC Au(I) 
complexes studied in this paper. Mes = 2,4,6-trimethylphenyl. 
 
RESULTS AND DISCUSSION 
Synthesis and Characterization.  
Starting from the sulfonated imidazolium salts a-d, three mono- (1-3) and a novel dinuclear (4) 
biscarbene Au(I) complexes have been synthesized (Scheme 1). The target compounds were 
obtained from an established two-step procedure consisting of the formation of silver carbene 
intermediates followed by the transmetalation to the Au(I) analogue.60 Ligands a-d and the 
respective complexes 1 and 2 were prepared based on published procedures.61–65 The synthesis 
of the Ag(I) precursors of 3 and 4 has been reported previously.65–68 However, to date no direct 
synthetic pathway for 3 has been published. In this study compound 3 was prepared by the 
straightforward reaction of the respective silver biscarbene complex and equimolar amounts of 
the transmetalation agent Au(SMe2)Cl. Complexes 3 and 4 were characterized by 
1H and 13C 
NMR spectroscopy, ESI-MS and elemental analysis. As expected for this class of compound,63 
the Au-Ccarbene signals clearly appear around 180 ppm in the 
13C NMR spectra (see Fig. 2, 4 in 
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SI). Compounds 1-4 are highly soluble in water (> 300 mg/mL) and exhibit high stability in air 
in solid state and dissolved in D2O for at least a month (no significant changes in the 
1H NMR 
spectra were observed). 
 
Scheme 1. Synthetic pathways of sulfonated mono- and dinuclear Au(I) NHC complexes 1-4. 
 
In addition, three novel monocarbene gold(I) complexes 8-10 featuring hydroxyl substituents 
were prepared (Scheme 2). The ligands e-g were synthesized in a two-step procedure starting 
from the neat reaction of 1H-imidazole and 1,2-epoxy-2-methylpropane. In contrast to the 
literature-known procedure by Yus et al. an excess of the epoxide was necessary at elevated 
temperature to yield 75% of 1-(1H-Imidazol-1-yl)-2-methylpropan-2-ol.69 In the next step the 
latter was quaternized by iodomethane, 1-butylchloride and benzyl bromide, to obtain the 
respective imidazolium salts e-g, while f was firstly published by Martin-Matute et al.70  
Compounds e-g were then deprotonated in the presence of a slight excess of Ag2O under the 
formation of silver carbene complexes 5-7. The reactions were performed at room temperature 
in dry dichloromethane except for 5, where little acetonitrile is needed for complete dissolution. 
After short reaction times (< 2 h) the ligand systems are fully converted to the silver complexes. 
The transmetalation reaction was performed by using equimolar amounts of Au(SMe2)Cl, 
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yielding the respective monocarbene Au(I) complexes 8-10 after 24 h at r.t. Compounds 8-10 
readily dissolve in solvents such as MeCN, CH2Cl2, acetone and DMSO but are only slightly 
soluble in water (< 10 mg/mL). They are stable in air both as a solid and in solutions of 
acetonitrile and DMSO (no significant changes in the 1H NMR spectra were observed) for at 
least one month. 
The signals in the 1H and 13C NMR spectra of ligands e-g appear as expected. Typically, upon 
quaternization of the nitrogen atom of ligand precursor 1-(1H-Imidazol-1-yl)-2-methylpropan-
2-ol the acidic proton signals at the C2 position are shifted downfield from 7.45 ppm to 8.73 
ppm, 9.30 ppm and 9.10 ppm, respectively. In addition, the hydroxyl proton signals of e-g give 
sharp singlets in the range of 3.60 ppm – 5.30 ppm. The assignment of these signals can be 
confirmed by the addition of one drop D2O to each sample in CD3CN which leads to their 
complete disappearance due to rapid hydroxyl proton exchange with deuterium.  
The 1H NMR spectra of silver complexes 5-7 display similar chemical shifts but, as expected, 
vary significantly in the absence of the acidic proton signal in the C2 position at 8.73 ppm (e), 
9.31 ppm (f) and 9.78 ppm (g), respectively, for the silver species. In the 13C NMR spectra the 
Ag-Ccarbene signals emerge in a narrow range from 184.51 ppm (5) to 181.36 (6). Due to the 
temperature-dependent fluxional behavior of Ag(I) NHC complexes in solution, the carbene 
carbon signals appear each as sharp singlets instead of doublet of doublets (based on the 
coupling constants of the silver isotopes 107Ag and 109Ag) at room temperature.71  
The Au(I) NHC compounds 8-10 have also been characterized by elemental analysis, 1H and 
13C NMR and ESI mass spectrometry. By means of 1H NMR spectroscopy the hydroxyl protons 
can be observed as sharp singlets at 2.93 ppm (8), 2.96 (9) and 2.99 (10), respectively (see Fig. 
11, 13, 15 in SI). These signals can be easily identified by proton exchange experiments with 
D2O (which lead to the disappearance of the singlets). Moreover, the formation of the Au(I) 
complexes is confirmed through 13C NMR spectroscopy, since the carbenes adjacent to the 
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more electron rich gold atom in 8-10 display upfield shifted signals (~10 ppm) compared to the 
respective silver species.  
 
Scheme 2. Synthesis of targeted hydroxylated gold(I) NHC complexes 8-10 via transmetalation 
of the respective silver compounds 5-7. 
 
Studies of stability in solution. 
Initially, the stability of the mono and bis(NHC) Au(I) complexes was investigated for 4 and 8. 
For this purpose, the compounds were incubated at 37 °C in aqueous solution and aliquots for 
TOF-MS analysis were taken after 30 min and 24 h, respectively. In solution, complex 8 rapidly 
hydrolyses and the parent signal vanishes within a few minutes. Instead, a single mass signal 
was observed at m/z 505.1992, suggesting the formation of the biscarbene of the type [(L1)2Au]
+ 
(mtheor = 505.1878, Table S1, supplementary material), where L
1 is the iPrOH-NHC ligand 
derived from e (Scheme 3, right). This mass signal is not observed in buffered solution (20 mM 
NH4CO3, pH 7.4) where the hydrolysis product of 8 seems to be stabilized by forming an 
ammine complex with the buffer component corresponding to [L1Au(NH3)]
+ found at m/z 
368.1270 (mtheor = 368.1037, Scheme 3, left). Thus, the complex moiety [Au(NHC)]
+ remains 
unaltered at 37 °C for at least 24 h and, as expected, the mono-carbenic Au(I) complex is 
reactive towards nucleophiles (as in NH3) and is able to undergo chloride exchange reactions, 
which is promising for further enzyme inhibition assays. In contrast, the bis(NHC) complex 4 
turned out to be exceptionally stable in aqueous solution and the parent mass signals 
([(L2)2Au2]
2- and [(L2)2Au2 + Na]
- with L2 being the deprotonated ligand d) are the only 
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detected signals from this compound in both aqueous and buffered solution for over 24 h 
(Table S1, Figure 5C).  
 
Scheme 3. Chemical behaviour of 8 in aqueous and buffer (20 mM NH4CO3, pH 7.4) solution 
as observed in MS studies. 
 
Inhibition of isolated TrxR and GR. 
In order to elucidate the reactivity towards the putative biological target, all Au(I) NHC 
complexes were initially in vitro evaluated for their inhibitory potential towards TrxR.  The 
gold(I) compounds 1-4 and 8-10 were tested against both purified cytosolic (TrxR1) and 
mitochondrial (TrxR2) thioredoxin reductase according to established protocols as described in 
the experimental section. In addition, the inhibition of glutathione reductase (GR), which 
exhibits a closely related structure to TrxR but lacks selenocysteine residues was investigated 
to determine the selectivity of enzyme binding. In Table 1 the half maximal inhibitory 
concentrations (IC50) of the NHC Au(I) complexes for enzyme inhibition are reported in 
comparison to bench-mark gold(I) compound auranofin. Most strikingly, the monometallic 
bis(NHC) complexes 1-3 were less efficient and could inhibit cytosolic TrxR at much higher 
concentrations (4.8-23 µM) than the monocarbenic compounds 8-10 (0.018-0.073 µM). These 
results are in line with previously reported studies on other Au(I) NHC systems.72–75 This 
finding correlates to the results from the stability investigations where a biscarbenic compound 
proves to be less prone to nucleophilic attack than a monocarbenic complex. Due to the higher 
stability of the two organometallic Au-C bonds the gold complexes 1-3 are most probably 
impeded to undergo facile ligand exchange reactions with Cys and/or Sec residues in order to 
bind to TrxR. Interestingly, the bimetallic bis(NHC) gold complex 4 is slightly more potent at 
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lower concentrations than its monometallic congeners 1-3, demonstrating that TrxR could be 
more efficiently targeted by doubling the amount of reactive gold centres. In comparison, the 
activity of TrxR is less influenced in the presence of the respective ligand d (4.8 µM) 
demonstrating the necessity of the gold centres for inhibition of the seleno-enzyme. 
Remarkably, the activity of cytosolic TrxR is efficiently inhibited by all three monocarbenic 
Au(I) complexes displaying IC50 values in the nanomolar range, comparable to auranofin, 
following the order of activity 9 > 10 > 8. Regarding the inhibition of mitochondrial thioredoxin 
reductase (TrxR2) the order of activity is slightly changed to 9 > 8 > 10. As expected, the 
inhibitory effect on both TrxR isoforms drops significantly by a 10-100-fold of magnitude, 
approximately, when treating with the metal-free ligand g instead of the respective complex 10. 
In comparison, in all cases the activity of GR is inhibited at substantially higher concentrations 
(> 10 µM), indicating a preferential binding mode especially of complexes 4 and 8-10 for 
purified TrxR. 
 
Table 1. Inhibition of cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductase, in 
comparison to glutathione reductase (GR). 
 
Compound TrxR1 TrxR2 GR 
 IC50 (µM)a  
d 4.8 ± 0.1 n.d. > 10 
g > 2  > 10 > 10 
1 5.1 ± 0.2 n.d. > 10 
2 23.0 ± 2.0 n.d. > 10 
3 3.66 ± 0.09 n.d. > 10 
4 0.41 ± 0.05 3.3 ± 0.09 > 10 
8 0.073 ± 0.002 0.31 ± 0.04 > 10 
9 0.018 ± 0.001 0.27 ± 0.02 > 10 
10 0.025 ± 0.003 0.5 ± 0.1 > 10 
auranofin 0.007 ± 0.001 0.004 ± 0.001 > 10 
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The compounds which show the strongest inhibitory activity towards TrxR (8-10) were 
preliminarily evaluated for their antiproliferative effects in the human ovarian cancer cell line 
2008. In addition, the dinuclear complex 4 was included due to its stronger TrxR inhibition 
compared to the other bis(NHC) compounds. For this purpose, the cells were treated with the 
respective gold compounds for different times over 24 h and the final cell viabilities were 
quantified using the MTT technique as detailed in the experimental section. Remarkably, 
whereas dinuclear biscarbenic 4 is not cytotoxic at a concentration of 60 µM, all three tested 
mono(NHC) Au(I) complexes are remarkably potent even after only 1 h of incubation time, 
displaying IC50 values in the low µM range (13.2 ± 3.5 µM, 17.5 ± 1.5 µM and 24.5 ± 4.2 µM) 
following the order of cytotoxicity 8 > 9 > 10 (Figure 2). At 24 h, the compounds cytotoxicity 
did not display significant differences, suggesting the idea that either reduced accumulation or 
compounds’ inactivation by extracellular components may be in place. It is worth mentioning 
that recently, Ott and coworkers reported on the negative effect of serum components of the 




Figure 2. Dose-dependent viability of ovarian carcinoma cells 2008 after 1 h of incubation in 
the presence of selected NHC Au(I) compounds 4 and 8-10. 
 
Inhibitory effects on TrxR and GR activity in cell lysates. 
In order to endorse a possible contribution of the TrxR inhibition of the compounds to their 
observed antiproliferative effects on cells, enzyme activity was also assessed in cell extracts 
from 2008 pre-treated with compounds 4 and 8-10 (20 µM, 40 µM and 60 µM) for 3 h (Figure 
3). For the dinuclear biscarbene complex 4, a negligible inhibition is obtained even at the 
highest examined concentration (60 µM), which correlates well with its observed non-
cytotoxicity (Figure 2). Notably, at a concentration close to the IC50 value for the 
antiproliferative effects (20 µM) monocarbenic gold species 8-10 cause a substantial decrease 
of thioredoxin reductase activity (> 70%) following the same order of antiproliferative activity 
8 > 9 > 10. A further increase of the compound concentration leads to a significant decline in 
TrxR activity, reaching ca. 90% inhibition at 60 µM. By contrast, GR activity is clearly less 
affected with approximately 50% inhibition only at higher complex concentrations. In 
comparison, ligand g is completely ineffective on both TrxR and GR activities (data not shown). 
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Hence, these studies coincide well with the order of observed enzyme selectivity TrxR > GR 
(Table 1) as well as the determined cytotoxicity, which appears to correlate well with the TrxR 
inhibition by the gold compounds.  
 
Figure 3. Total thioredoxin reductase (TrxR) and glutathione reductase (GR) activities in 2008 
cell lysates. Cells (7 x 105) were treated with compounds 4 and 8-10 at the indicated 
concentrations in PBS/10 mM glucose medium as described in the experimental section. After 
3 h, the cells were lysed and processed. (A) TrxR activity (B) GR activity. 
 
BIAM assay. 
It was of further interest to investigate possible binding sites and thus the status of the C-
terminal redox active centre of reduced TrxR when treated with the mono(NHC) gold 
complexes 8-10 and, for comparative reasons, with bis(NHC) species 1-3. For this purpose, the 
BIAM assay, a reliable biochemical method using BIAM (biotin-conjugated iodoacetamide) 
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which can alkylate TrxR in a pH-dependent manner, was applied. Based on the different pKa 
values of Cys (8.577) and Sec (5.278) at pH 6.0 only selenocysteine (and low pKa cysteines) are 
alkylated, whereas at pH 8.5 both Cys and Sec are modified. The labelled enzymes were 
detected with horseradish peroxidase-conjugated streptavidin, triggering chemiluminescence 
(see experimental section for details). However, pre-treatment of TrxR with thiol- and/or 
selenol-binding species (such as gold) blocks BIAM-binding and thus reduces the 
chemiluminescent effect. The obtained results are shown in Figure 4. 
The blotting band intensities after the treatment of 100 µM of gold complexes 1-3 indicate a 
generally poor interaction with the enzyme although a slight preference for Sec is observed for 
1 and 2. In accordance with the TrxR inhibition (see results above), 100 µM of compounds 8 
and 9, respectively, completely derivatize the enzyme at pH 6 implying their strong binding to 
selenol groups, but also with Cys as it appears at pH 8.5. However, in contrast to 8, a slight 
preference for Sec is observed for 9. On the other hand, lower concentrations of compound 10 
(e.g. 20 µM) are sufficient to significantly and to some extent selectively bind to selenol groups 
(Figure 4B: 42%, lane d vs. 58%, lane d’). The immunoblotting indicates a strong TrxR-binding 
of the three mono(NHC) Au(I) complexes, where a slight binding preference for Sec is observed 
for 9 and 10.  
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Figure 4. BIAM assay after treatment of TrxR with selected Au(I) NHC compounds. A: gold 
compounds (100 µM) were incubated with TrxR (1 μM). Then, aliquots (8 μL) of the reaction 
mixture were added to 50 μM biotinylated iodoacetamide (BIAM) in buffer either at pH 6 (0.1 
M Hepes-Tris) or pH 8.5 (0.1 M Tris-HCl). The samples were subjected to SDS-PAGE as 
described in the experimental section. Volumes of densitometric analysis were shown in the 
lower panel. B: Interaction of compound 10 with TrxR was analyzed at different concentrations 
(a: none; b: 5 µM; c: 10 µM; d: 20 µM) and densitometric analysis is reported (Nine Alliance 
software).  
 
MS studies on interactions with mixtures of amino acids and tripeptide GSH.  
The mechanisms of action of metal-based therapeutic agents are at least partly dictated by the 
molecular reactivity of the respective agent. Thus, characterizing activation mechanisms and 
ligand exchange reactions especially under competitive conditions give insights into potential 
binding preferences in the cellular context.79,80 Previously reported studies, showed that the 
binding preferences of several organometallic and coordination Au(III) compounds with 
selenocysteine (Sec) correlate well with the inhibitory effect on TrxR and their antiproliferative 
activity.81 
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The reported approach was further extended to two representative Au(I) NHC compounds, 
namely to bimetallic bis(NHC) 4 and the most cytotoxic complex 8. In order to investigate the 
binding preferences towards differently functionalized amino acids in a competitive manner, 
e.g. as in proteins, the complexes were treated with mixtures of Glu (carboxylic acid), His 
(imine), Met (thioether) and Cys (thiol). The amino acids were chosen based on previous 
literature providing indications for their gold-binding character.20,82 In order to obtain additional 
information on the selectivity towards the selenol residue at the C-terminal site of TrxR, the 
mixture was extended by Sec. Furthermore, the interaction with tripeptide glutathione (GSH), 
which acts e.g. in the protection of cellular components against ROS, was tested. For this 
purpose, the reactivity of the compounds was separately investigated over 24 h in the presence 
of a Glu : His : Met : Cys (1:1:1:1) mixture, a mixture of Glu : His : Met : Cys : Sec (1:1:1:1:1) 
and GSH alone, respectively. The reactions were carried out in purely aqueous solution and in 
buffered solution using ammonium carbonate (20 mM, pH 7.4), respectively. 
Studies on the binding character of the bimetallic Au(I) complex 4 display only parent mass 
signals in the presence of GSH and the amino acid mixtures, respectively, in both aqueous and 
buffered solution over 24 h (see Figure 5C). This observed exceptional stability towards 
nucleophiles is in accordance with the weak enzyme inhibition in 2008 cell lysates (Fig. 3) and 
could substantiate the non-cytotoxic effect as described above (Fig. 2).  
The reaction between 8 and substrate GSH under both aqueous and buffered conditions yields 
reaction prodrugs corresponding to [Au + GSH – 2H]-, [L1Au + GSH – 2H]- and [2(L1Au) + 
GSH – H]+ (Figure 5A left, Table S1). Less intense mass signals can be observed in buffered 
solution suggesting that ammine coordination (see Scheme 3) may be responsible for the 
reduced reaction kinetics compared to purely aqueous solution.  
Interestingly, when exposing mono(NHC) Au(I) compound 8 to a mixture of amino acids 
containing Glu : His : Met : Cys in buffer and aqueous solution, cysteine adducts corresponding 
to [L1Au + Cys – 2H]- (m/z = 470.0845, mtheor = 470.0813, Table S1) and [2(L1Au) + Cys – H]+ 
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(m/z = 822.1796, mtheor = 822.1901, Table S1) (Figures 5A right, 6A) are exclusively formed 
and no reaction with Glu, His and Met is observed after 24h. Similar adducts are also observed 
in the presence of both Cys and Sec when incubated with the mixture containing 
Glu : His : Met : Cys : Sec in aqueous solution (Figure 6B). Notably, additional mass signals of 
gold adducts with selenocysteine as in [L1Au + Sec – 2H]- (m/z = 518.0275, mtheor = 518.0284, 
Table S1) (Figure 5B) and [2(L1Au) + Sec - H]+ (m/z = 870.1276, mtheor = 870.1372, Table S1) 
(Fig. 6B) are also observed. Therefore, it is suggested that complex 8 hydrolyses the chlorido 
ligand and interacts with both selenocysteines and cysteine, which is in accordance with the 




Figure 5. Experimental and simulated mass spectra of several identified Au reaction products: 
(A) The reaction between 8 and GSH alone (left); and between 8 and Glu : His : Met : Cys 
yielded L1Au-GSH and L1Au-Cys adducts (right) under buffered conditions. (B) In purely 
aqueous conditions, the reaction between 8 and Glu : His : Met : Cys : Sec yielded an L1Au-
Sec adduct in addition to the Cys adduct. (C) Compound 4 is stable towards amino acids and 




Figure 6. Compound 8 was incubated with an equimolar mixture of Glu : His : Met : Cys (A) 
and Glu : His : Met : Cys : Sec (B) in aqueous solution for 24 h. 
 
ROS production in the presence of gold compounds. 
Reactive oxygen species (ROS) are products of the physiological mitochondrial cell 
metabolism and are involved in cellular redox homeostasis. Their formation may perturb the 
cellular antioxidant defence system. It has been shown previously that TrxR inhibition alters 
cell conditions causing an increase of H2O2 concentration, as well as an imbalance of the 
cellular redox state leading to mitochondrial membrane permeabilization (MMP), cell swelling 
and thus apoptosis. In this study, the effect of gold compounds 8-10 (10 µM – 30 µM) on the 
ROS production was evaluated in 2008 ovarian cancer cells over a period of 2 h using the 
peroxide-sensitive fluorescent probe CM-H2DCFDA (see Experimental section for details). In 
Figure 7 the results of gradual ROS formation detected in the presence of 20 µM compounds 
are reported. Overall, all of the three gold compounds stimulate ROS formation. Among these, 
in particular complex 8 induces the highest amount of ROS, which is in good agreement with 
the results from the cytotoxicity assay and the strongest inhibitory effect towards the redox-
related enzyme TrxR. 
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Figure 7. Cellular ROS estimation with CM-H2DCFDA. Ovarian cancer cells 2008 (1 x 10
4) 
were treated in PBS/10 mM glucose with 20 µM gold compounds. Reaction was followed as 
fluorescence increase as described in Experimental details. Wavelengths: Ex 485 nm, Em 527 
nm. 
 
Interactions with G-quadruplexes by FRET melting assay. 
In order to gain further mechanistic insights and inspired by our recent results that highlighted 
the exquisite G4-quadruplex selectivity of the bis(caffeine) complex AuTMX2 against 
telomeric G4-DNA, we subsequently investigated the properties of representative bis(NHC) 
complexes 2-4 and the most potent species 8 as G-quadruplex DNA stabilizers.43 Experiments 
were performed with the most classically used G-quadruplex-forming oligonucleotide F21T, 
which mimics the human telomere sequence (FAM-d[5′G3(T2AG3)3
3′]-TAMRA). The stability 
imparted by a ligand (expressed as ΔT1/2 values, in °C) is readily monitored through the 
modification of the FRET phenomenon (fluorescence resonance energy transfer) and enables 
an easy quantification of its apparent affinity for quadruplex-DNA. Thus, the compounds 
(1 M) were incubated with fixed amounts of G4 for 10 min at room temperature as described 
in the experimental section. The AuTMX2 complex was also screened for the purpose of 
comparison. 
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As it can be observed in Figure 8, none of the newly tested Au(I) NHC complexes is able to 
substantially induce the stabilization of the G4 structure, confirming their binding preferences 
to protein targets such as TrxR. 
 
Figure 8. FRET melting results of experiments carried out with 0.2 μM DNA (FAM-
d[5′G3(T2AG3)3
3′]-TAMRA, hTelo) without (black curve) or with Au(I) NHC complexes 
(colored curves) in 60 mM potassium cacodylate buffer (pH 7.4). 
 
CONCLUSION 
A series of novel hydroxylated mono(NHC) Au(I) and mono- and dinuclear gold compounds 
featuring sulfonated bis(NHC) ligands is reported. The compounds have been comparatively 
screened for their inhibitory effects on purified TrxR and GR and on cell extracts in vitro. In 
contrast to the sulfonated bis(NHC) Au(I) complexes, all three monocarbenic compounds are 
considerably selective at targeting the seleno-enzyme TrxR over glutathione reductase. In fact, 
the most active inhibitors are the Au(I) monocarbene complexes 8-10 with similar IC50 values 
as auranofin in the nanomolar range. The same compounds were also tested for their 
antiproliferative effects on the human ovarian cancer cell line 2008 and display promising 
activity (8 > 9 > 10) after only 1 h of incubation time. Notably, a similar order of activity is 
observed for the inhibition of TrxR in 2008 cell lysates, indicating a possible correlation 
between the protein binding and the cytotoxic effect.  
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The proposed mechanism of TrxR inhibition involves direct coordination of the Au(I) center to 
the Sec in the enzyme active site, as suggested by the limited inhibition of the enzyme 
glutathione reductase lacking the Sec-containing domain. However, two independent 
techniques, namely BIAM assays and mass spectrometric studies confirm possible binding of 
Sec and Cys. Notably, the selected compounds show high selectivity towards protein targets 
with respect to nucleic acids as determined via FRET melting assays with telomeric G-
quadruplex DNA.  
Thus, the obtained results clearly indicate a correlation between cytotoxicity and TrxR 
inhibition in cancerous cells; however, further studies are necessary to validate our mechanistic 
hypothesis and to exclude other possible intracellular targets. It should also be noted that the 
obtained MS results on the stability of the complexes in solution indicate bis-carbene formation 
from mono-carbenes in buffered aqueous solution. The latter type of reactivity has never been 
described before for similar systems. In general, the influence of buffer and cell culture media 
components (including serum proteins) on the metallodrug speciation should be always 
considered to avoid compound’s deactivation as well as to determine the real pharmacologically 
active species. For example, the negative influence of serum proteins on Au(I) NHC complexes 
cellular accumulation has been demonstrated recently demonstrated.76 
Finally, while the hydroxylated mono(NHC) gold(I) complexes 8-10 display promising 
anticancer activities and the selected scaffolds constitute attractive leads for further drug design, 
the quest for selectivity of such complexes towards cancer cells needs still to be addressed. In 
fact, recent ex vivo studies on mono- and bis-NHC Au(I) compounds, featuring a 1-butyl-3-
methyl-imidazol-2-yilidene scaffold, demonstrated that the compounds display severe toxicity 
in healthy kidney tissue, even higher than cisplatin, while being potent anticancer agents in 
vitro.83 We suggest that, in order to improve gold NHC complexes selectivity, the robust 
carbene scaffold may be derivatized to conjugate the metal complex to targeting moieties, such 
as peptides and antibodies. 
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EXPERIMENTAL DETAILS 
General. All synthetic manipulations were performed under an argon atmosphere using 
standard Schlenk techniques. Solvents were obtained water-free from an Mbraun solvent 
purification system. Deionized water (type II quality) was obtained with a Millipore Elix 10 
UV Water Purification System. All other reagents were purchased from commercial suppliers 
and were used without further purification. All reactions including silver carbene compounds 
as reactant or product were performed under exclusion of light. 
Ligand precursor 1-(2,4,6-Trimethylbenzyl)-1H-imidazole84 and ligands 3-(1-Methyl-1H-
imidazol-3-ium-3-yl)propane-1-sulfonate (a)61, 3-(1-Butyl-1H-imidazol-3-ium-3-yl)propane-
1-sulfonate (b)62, 3-(1-Mesityl-1H-imidazol-3-ium-3yl)propane-1-sulfonate (c)66, zwitterionic 
ligand d65 and 3-Butyl-1-(2-hydroxy-2-methylpropyl)-1H-imidazol-3-ium chloride (f)70 were 
prepared according to the given literature. Gold(I) NHC complexes 1 and 2 were prepared based 
on published synthetic procedures.63  
For the characterization of compounds NMR spectra were recorded on a Bruker Avance III 
400. Chemical shifts are given in parts per million (ppm) and the spectra were referenced by 
using the residual solvent shifts as internal standards (1H NMR: CDCl3, δ 7.26; CD3OD, δ 3.31; 
CD3CN, δ 1.94; D2O, δ 4.79; 13C NMR: CDCl3, δ 77.16; CD3OD, δ 49.00; CD3CN, δ 1.32). 
Electrospray ionization (ESI) mass spectrometry (MS) analyses were performed on a Thermo 
Scientific LCQ/Fleet spectrometer by Thermo Fisher Scientific. Elemental analysis was 
obtained from the microanalytical laboratory of TUM. 
 
Synthetic Procedures. 1-(1H-Imidazol-1-yl)-2-methylpropan-2-ol. The synthesis is performed 
according to a modified procedure by Yus et al.69 1H-Imidazole (3.0 g, 44 mmol, 1.0 equiv.) 
and 1,2-epoxy-2-methylpropane (5.1 mL, 57 mmol, 1.3 equiv.) are stirred at 60°C for 22 h 
under argon atmosphere. The reaction mixture is rinsed with Et2O and then dried under vacuum. 
The product is obtained as colorless solid (4.6 g, 75%). 1H NMR (CDCl3): δ = 7.44 (s, 1H, 
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NCHN), 6.92 (s, 1H, NCHCHN), 6.90 (s, 1H, NCHCHN), 4.18 (s, 1H, OH), 3.84 (s, 2H, 
NCH2), 1.19 (s, 6H, C(CH3)2). 
1H NMR (CD3CN): δ = 7.45 (s, 1H, NCHN), 7.03 (s, 1H, 
NCHCHN), 6.88 (s, 1H, NCHCHN), 3.87 (s, 2H, NCH2), 1.11 (s, 6H, C(CH3)2). 
13C NMR 
(CDCl3): δ = 138.28, 128.07, 120.82, 69.75, 58.10, 27.10.  
 
1-(2-Hydroxy-2-methylproply)-3-methyl-1H-imidazol-3-ium iodide (e). In a pressure tube a 
solution of 1-(1H-Imidazol-1-yl)-2-methylpropan-2-ol (3.06 g, 21.9 mmol, 1 equiv.) and 
methyl iodide (1.36 mL, 21.9 mmol, 1 equiv.) in acetonitrile (15 mL) is heated at 80°C for 2 h. 
The solvent is evaporated under vacuum at 40°C and the resulting oily raw product is rinsed 
with CHCl3. Filtration and subsequent drying under vacuum affords a yellow solid (4.3 g, 69%). 
1H NMR (CD3CN): δ = 8.73 (s, 1H, NCHN), 7.48 (t, 1H, NCHCHN), 7.37 (t, 1H, NCHCHN), 
4.18 (s, 2H, NCH2), 3.87 (s, 3H, NCH3), 3.61 (s, 1H, OH), 1.19 (s, 6H, C(CH3)2). 
13C NMR 
(CD3CN): δ = 137.74, 124.84, 123.65, 69.89, 59.96, 37.01, 26.89. MS-ESI (m/z): [5 - I]+ calc’d, 
155.12; found, 155.04.  
 
3-Benzyl-1-(2-hydroxy-2-methylpropyl)-1H-imidazol-3-ium bromide (g). In a pressure tube a 
solution of 1-(1H-Imidazol-1-yl)-2-methylpropan-2-ol (2.00 g, 14.3 mmol, 1.00 equiv.) and 
benzyl bromide (2.04 mL, 17.1 mmol, 1.20 equiv.) in toluene (20 mL) is heated at 100°C for 
18 h. The resulting oil is separated from the residual solvent and washed with toluene (3 x 10 
mL). After drying via rotary evaporator the product is obtained as brown oil (4.18 g, 94%). 1H 
NMR (CD3CN): δ = 9.10 (s, 1H, NCHN), 7.54 (t, 1H, NCHCHN), 7.46-7.41 (m, 5H, ArH), 
7.39 (t, 1H, NCHCHN), 5.40 (s, 2H, NCH2(C6H5)), 5.01 (s, 1H, OH), 4.23 (s, 2H, 
NCH2C(CH3)2OH), 1.17 (s, 6H, C(CH3)2). 
13C NMR (CD3CN): δ = 137.72, 135.09, 130.16, 
130.05, 129.49, 125.40, 122.30, 69.68, 59.99, 53.69, 26.95. MS-ESI (m/z): [7 - Br]+ calc’d, 
231.32; found, 231.20.  
 
 25 
Sodium[1-mesityl-3-(3-sulfonatopropyl)imidazole-2-ylidene]gold(I) (3). For the synthesis of 
the Ag(I) intermediate a modified procedure of a literature-known process was used.66 Ligand 
c (260 mg, 0.84 mmol, 1.0 equiv.) is dissolved in deionized water (10 mL) and Ag2O (195 mg, 
0.84 mmol, 1.0 equiv.) is added. After the suspension has been stirred at 50°C for 22 h NaCl 
(49 mg, 0.84 mmol, 1.0 equiv.) is added and the mixture is stirred for 30 min at r.t. After 
filtration over Celite® Au(SMe2)Cl (124 mg, 0.42 mmol, 0.5 equiv.) is added to the clear 
solution and is stirred at r.t. overnight. The solvent is evaporated at 40°C under reduced 
pressure, re-dissolved with methanol and filtered three times over Celite®. The compound is 
obtained as colorless solid after drying in vacuo (300 mg, 85%). 1H NMR (CD3OD): δ = 7.58 
(d, 3JH-H = 1.89 Hz, 2H, H
Im), 7.22 (d, 3JH-H = 1.87 Hz, 2H, H
Im), 7.05 (s, 4H, m-HMesityl), 4.04 
(t, 3JH-H = 6.83 Hz, 4H, NCH2CH2CH2), 2.57 (t, 
3JH-H = 7.4 Hz, 4H, NCH2CH2CH2), 2.38 (s, 
6H, p-CH3
Mesityl), 2.15-2.08 (m, 4H, NCH2CH2CH2), 1.88 (s, 12H, o-CH3
Mesityl). 13C NMR 
(CD3OD): δ = 185.56, 141.16, 136.40, 136.34, 130.41, 124.42, 123.55, 49.86, 48.92, 28.37, 
21.30, 17.74. MS-ESI (m/z): [10-Na+2H]+ calc’d, 813.20; found, 813.45; [10+H]+ calc’d, 
835.19; found, 835.38; [10+Na]+ calc’d, 857.17; found, 857.62. Elem. Anal. Calc’d for 
C30H38AuN4NaO6S2·NaCl: C, 40.34; H, 4.29; N, 6.27; S, 7.18; Found: C, 40.68; H, 4.53; N, 
6.22; S, 7.28. 
 
Disodium[1,1’-methyl-bis(3-(sulfonatopropyl)imidazole-2-ylidene]gold(I)] (4). The synthesis 
of the respective silver(I) intermediate is performed according to previous literature.68 Ligand 
d (209 mg, 0.53 mmol, 1.0 equiv.) is dissolved in deionized water (10 mL) and Ag2O (123 mg, 
0.53 mmol, 1.0 equiv.) is added. After the suspension is stirred at 50°C for 2 h, NaCl (34 mg, 
0.58 mmol, 1.1 equiv.) is added and the mixture is stirred for 30 min at r.t. After filtration over 
Celite® Au(SMe2)Cl (157 mg, 0.53 mmol, 1.0 equiv.) is added to the clear solution and is 
stirred at r.t. overnight. The solvent is evaporated at 45°C under reduced pressure, re-dissolved 
with deionized water and filtered three times over Celite®. The compound is obtained as 
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colorless solid after drying in vacuo (238 mg, 73%). 1H NMR (D2O): δ = 7.50 (s, 4H, HIm), 7.36 
(d, 4H, HIm), 6.96 (d, 2JH-H = 13.99 Hz, 2H, NCH2N), 6.14 (d, 
2JH-H = 13.99 Hz, 2H, NCH2N), 
4.33-4.28 (m, 8H, NCH2CH2CH2), 2.86-2.80 (m, 8H, NCH2CH2CH2), 2.27 (t, 
3JH-H = 6.91 Hz, 
8H, NCH2CH2CH2). 
13C NMR (D2O/CD3OD): δ = 184.28, 123.95, 122.45, 64.08, 51.00, 48.68, 
27.30. MS-ESI (m/z): [10-2Na+3H]+ calc’d, 1117.09; found, 1177.09; [10-Na+2H]+ calc’d, 
1199.07; found, 1199.07; [10+H]+ calc’d, 1221.05; found, 1221.05; [10+3Na]+ calc’d, 
1243.04; found, 1243.04. Elem. Anal. Calc’d for C26H36Au2N8Na2O12S4: C, 25.58; H, 2.97; N, 
9.18; Found: C, 25.31; H, 3.05; N, 9.01. 
 
 
[3-Methyl-1-(2-hydroxy-2-methylpropyl)imidazol-2-ylidene]silver(I) iodide (5). To a solution 
of 1-(2-hydroxy-2-methylproply)-3-methyl-1H-imidazol-3-ium iodide (100 mg, 0.35 mmol, 
1.00 equiv.) in dry CH2Cl2/MeCN = 6/1 (3.5 mL) Ag2O (44.0 mg, 0.19 mmol, 0.53 equiv.) is 
added. This suspension is stirred for one hour at room temperature. The mixture is then filtered 
over Celite® and used for the subsequent transmetalation step. 1H NMR (CD3CN): δ = 7.20 (d, 
3JH-H = 1.76 Hz, 1H, H
Im), 7.12 (d, 3JH-H = 1.73 Hz, 1H, H
Im), 4.12 (s, 2H, NCH2), 3.84 (s, 3H, 
NCH3), 1.17 (s, 6H, C(CH3)2). 
13C NMR (CD3CN): δ = 184.54, 124.01, 122.81, 70.59, 62.29, 
39.13, 27.63. 
 
[3-Butyl-1-(2-hydroxy-2-methylpropyl)imidazol-2-ylidene]silver(I) chloride (6). The silver 
carbene intermediate is synthesized based on a previous literature.70 Imidazolium salt f (225 
mg, 0.97 mmol, 1.00 equiv.) is dissolved in dry CH2Cl2 (6 mL) and Ag2O (119 mg, 0.51 mmol, 
0.53 equiv.) is added subsequently. After the reaction mixture is stirred for two hours at room 
temperature, it is filtered over Celite® and used for the subsequent transmetalation step. 1H 
NMR (CD3CN): δ = 7.23 (d, 3JH-H = 1.82 Hz, 1H, HIm), 7.15 (d, 3JH-H = 1.76 Hz, 1H, HIm), 4.09-
4.05 (m, 4H, NCH2C(CH3)2OH, NCH2(CH2)2CH3), 1.79-1.71 (m, 2H, NCH2CH2CH2CH3), 
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1.33-1.23 (m, 2H, N(CH2)2CH2CH3), 1.28 (s, 6H, C(CH3)2), 0.90 (t, 
3JH-H = 7.30 Hz, 3H, 
N(CH2)3CH3). 
13C NMR (CD3CN): δ = 181.43, 124.41, 121.46, 70.23, 62.80, 52.18, 34.34, 
28.03, 20.40, 14.01. 
 
[3-Benzyl-1-(2-hydroxy-2-methylpropyl)imidazol-2-ylidene]silver(I) bromide (7). Imidazolium 
salt g (300 mg, 0.96 mmol, 1.00 equiv.) is dissolved in CH2Cl2 (7 mL) and Ag2O (134 mg, 0.58 
mmol, 0.60 equiv.) is added. The suspension is stirred for 45 minutes at room temperature. The 
mixture is then filtered over Celite® and used for the subsequent transmetalation step. 1H NMR 
(CD3CN): δ = 7.32-7.17 (m, 6H, HPhenyl, HIm), 7.16 (d, 3JH-H = 1.80 Hz, 1H, HIm), 5.28 (s, 2H, 
NCH2(C6H5)), 4.08 (s, 2H, NCH2C(CH3)2OH), 1.13 (s, 6H, C(CH3)2). 
13C NMR (CD3CN): δ = 
183.45, 138.28, 129.89, 129.13, 128.47, 124.75, 121.99, 121.87, 70.41, 62.59, 55.69, 49.74, 
27.65. 
 
[3-Methyl-1-(2-hydroxy-2-methylpropyl)imidazol-2-ylidene]gold(I) chloride (8). A mixture of 
Au(SMe2)Cl (104 mg, 0.35 mmol, 1.0 equiv.) and the silver carbene mixture 5 (136 mg, 0.35 
mmol, 0.10 M in CH2Cl2/MeCN) is stirred at room temperature overnight. The crude product 
is filtered over Celite® and dried under reduced pressure to obtain a pale yellow powder in 49% 
yield (66.3 mg). 1H NMR (CD3CN): δ = 7.21 (d, 3JH-H = 2.0 Hz, 1H, HIm), 7.09 (d, 3JH-H = 1.92 
Hz, 1H, HIm), 4.12 (s, 2H, NCH2), 3.78 (s, 3H, NCH3), 2.93 (s, 1H, OH), 1.19 (s, 6H, N(CH3)2). 
13C NMR (CD3CN): δ = 172.03, 123.64, 122.68, 70.61, 61.77, 38.62, 27.81. 1H NMR (CDCl3): 
δ = 7.24 (d, 3JH-H = 1.95 Hz, 1H, HIm), 6.92 (d, 3JH-H = 1.98 Hz, 1H, HIm), 4.19 (s, 2H, NCH2), 
3.84 (s, 3H, NCH3), 2.00 (s, 1H, OH), 1.28 (s, 6H, C(CH3)2). 
13C NMR (CD3Cl): δ = 172.04, 
122.65, 122.70, 70.63, 61.77, 38.65, 27.83. MS-FAB (m/z): [11-Cl]+ calc’d, 351.08; found, 
351.00. Elem. Anal. Calc’d for C8H14AuClN2O*0.1MeCN: C, 25.21; H, 3.69; N, 7.53; Found: 
C, 25.34; H, 3.75; N, 7.26.  
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[3-Butyl-1-(2-hydroxy-2-methylpropyl)imidazol-2-ylidene]gold(I) chloride (9). Au(SMe2)Cl 
(285 mg, 0.97 mmol, 1.00 equiv.) is added to the silver carbene mixture 6 (329 mg, 0.97 mmol, 
0.16 M in MeCN) and the suspension is stirred at room temperature overnight. The crude 
product is filtered over Celite® and dried under reduced pressure. The product is yielded as an 
orange powder (86.0 mg, 43%). 1H NMR (CDCl3): δ = 7.23 (d, 3JH-H = 1.97 Hz, 1H, HIm), 6.92 
(d, 3JH-H = 1.98 Hz, 1H, H
Im), 4.21-4.16 (m, 4H, NCH2C(CH3)2OH, NCH2(CH2)2CH3), 2.61 (s, 
1H, OH), 1.86-1.79 (m, 2H, NCH2CH2CH2CH3), 1.40-1.32 (m, 2H, N(CH2)2CH2CH3), 1.28 (s, 
6H, C(CH3)2), 0.95 (t, 
3JH-H = 7.39 Hz, N(CH2)3CH3). 
13C NMR (CDCl3): δ = 171.41, 122.57, 
120.00, 70.89, 61.08, 51.30, 33.20, 27.86, 19.79, 13.79. MS-ESI (m/z): [12-Cl+MeCN]+ calc’d, 
434.15; found, 434.10. Elem. Anal. Calc’d for C11H20AuClN2O: C, 30.82; H, 4.70; N, 6.53; 
Found: C, 31.13; H, 4.94; N, 6.35.  
 
[3-Benzyl-1-(2-hydroxy-2-methylpropyl)imidazol-2-ylidene]gold(I) chloride (10). A mixture of 
Au(SMe2)Cl (284 mg, 0.96 mmol, 1.0 equiv.) and the silver carbene mixture 7 (403 mg, 0.96 
mmol, 0.14 M in CH2Cl2) is stirred at room temperature overnight. The crude product is filtered 
over Celite® twice and dried under reduced pressure. The resulting oil is rinsed with n-pentane 
to obtain a green solid in 54% yield (240 mg). 1H NMR (CD3CN): δ = 7.40-7.33 (m, 5H, ArH), 
7.25 (d, 3JH-H = 2.0 Hz, 1H, H
Im), 7.14 (d, 3JH-H = 2.0 Hz, 1H, H
Im), 5.38 (s, 2H, NCH2(C6H5)), 
4.16 (s, 2H, NCH2C(CH3)2OH), 3.28 (s, 1H, OH), 1.20 (s, 6H, N(CH3)2). 
13C NMR (CD3CN): 
δ = 172.15, 137.74, 129.87, 129.23, 128.56, 124.36, 121.66, 70.63, 62.01, 55.24, 27.84. MS-
ESI (m/z): [14-Cl+MeCN]+ calc’d, 468.13; found, 468.10. Elem. Anal. Calc’d for 
C14H18AuClN2O: C, 36.34; H, 3.92; N, 6.05; Found: C, 36.38; H, 4.10; N, 5.84.  
 
Enzymatic activity estimation of isolated TrxR1, TrxR2 and GR 
Stock solutions of the complexes 10 mM in DMSO were prepared. Highly purified cytosolic 
(TrxR1) and mitochondrial (TrxR2) thioredoxin reductase were prepared from rat liver 
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according to what was previously reported by Luthman and Holmgren85 and by Rigobello and 
Bindoli86, respectively. The protein content of purified enzyme preparations was measured 
according to Lowry et al.87. Thioredoxin reductase activity was determined by estimating the 
DTNB-reducing property of the enzymes in the presence of NADPH. Aliquots of highly 
purified TrxR1 or TrxR2 in 0.2 M NaKPi buffer (pH 7.4), 5 mM EDTA and 0.25 mM NADPH 
were incubated with the various compounds. Afterward, the reaction was initiated with 1 mM 
DTNB and monitored spectrophotometrically at 412 nm.  
GR activity (yeast glutathione reductase) was measured in 0.2 M Tris-HCl buffer (pH 8.1), 1 
mM EDTA, and 0.25 mM NADPH in the presence of the various compounds. The assay was 
started by addition of 1 mM GSSG and followed spectrophotometrically at 340 nm. 
 
BIAM assay 
TrxR (1 μM) pre-reduced in the presence 60 μM NADPH, was incubated with gold compounds 
for 30 min at room temperature, in 50 mM Tris-HCl buffer (pH 7.4) containing 200 μM 
NADPH and 1 mM EDTA. After incubation, 8 μL of the reaction mixture was added to 8 µL 
of 100 μM biotinylated iodoacetamide (BIAM) in 0.1 M Tris-HCl at pH 8.5 or in 0.1 M Hepes-
Tris pH 6.0.88 Samples were incubated at room temperature for an additional 30 min to allow 
BIAM alkylation of free -SH/SeH groups of the enzyme. Then, BIAM-modified enzyme was 
subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 
10% gel, and transferred to a nitrocellulose membrane. BIAM labelled enzyme was detected 




Cell viability was determined with the 3-[4,.5-dimethylthiazol-2-yl]-2,.5- diphenyltetrazolium 
bromide (MTT) reduction assay. 2008 cells (1x104) were seeded in complete medium for 24 h. 
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Then, cells were washed and incubated in PBS/10 mM glucose for 1h in presence of increasing 
concentrations of gold compounds. At the end of the treatment, medium was removed and cells 
were washed and treated for 3 h at 37 °C with 0.5 mg/mL MTT dissolved in phosphate-buffered 
saline (PBS). Afterward, MTT solution was removed and 100 μL of stop solution (90% 
isopropanol, 10% DMSO) were added to each well. After 15 min, the absorbance at 595nm and 
690 nm was estimated using a plate reader (Tecan Infinite® M200 PRO). For MTT analysis, 
the experiments are the mean with SD of, at least, three different experiments, in replicates. 
 
Determination of TrxR and GR activities in cell lysates  
The human ovary 2008 cells were cultured in DMEM medium supplemented with 10% FBS 
and 1% penicillin/streptomycin (Invitrogen) at 37 °C in a humidified atmosphere of 95% air 
and 5% CO2. Cells (7x105) were seeded and after 24 h, washed twice and incubated for 3 h in 
the presence of gold complexes diluted in PBS/10mM glucose at increasing concentrations (20-
60 µM). Then harvested and washed with PBS. Each sample was lysed with a modified RIPA 
buffer: 150 mM NaCl, 50 mM Tris–HCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5% 
DOC, 1 mM NaF and an antiprotease cocktail (“Complete” Roche, Mannheim, Germany) 
containing 0.1 mM PMSF. After 40 min at 4 °C, the lysates were centrifuged at 12000g for 6 
min. The obtained supernatants were tested for enzymatic activities. Aliquots (50 µg) of lysates 
were subjected to thioredoxin reductase determination in a final volume of 250 µL of 0.2 M 
NaKPi buffer (pH 7.4), 5 mM EDTA, and 2 mM DTNB. After 2 min the reaction was started 
with 0.4 mM NADPH. Glutathione reductase activity was estimated on 50 µg protein in 0.2 M 
Tris-HCl buffer (pH 8.1), 1 mM EDTA, and 0.25 mM NADPH. The measurement was started 
adding 1 mM GSSG and followed spectrophotometrically at 340 nm. 
 
Estimation of ROS production 
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ROS generation in 2008 cell line was assessed using the fluorogenic probe CM-H2DCFDA 
(Molecular Probes, Invitrogen). Cells (1x104) were seeded in 96-wells plate, and, after 24 h, 
washed in PBS/10 mM glucose and loaded with 10 µM dye for 20 min in the dark at 37 °C. 
Afterwards, cells were washed with the same medium and incubated with gold complexes at 
20 µM final concentration. Fluorescence increase was estimated on a plate reader (Tecan 
Infinite® M200 PRO, Männedorf, CH)) at 485 nm (excitation) and 527 nm (emission) for 1.5 h. 
 
Mass spectrometry studies 
Stock solutions of 10 mM were prepared of 4 in water and of 8 in DMSO and prior the 
experiments. The compounds were incubated at 37 °C alone or in the presence of GSH (1 
equiv.) and aliquots were taken after 30 min and 24 h. The compounds were similarly incubated 
and sampled with a mixture of Glu : His : Met : Cys (1 : 1 : 1 : 1 : 1) and 
Glu : His : Met : Cys : SeCys (1 : 1 : 1 : 1 : 1 : 1), respectively. l-Selenocysteine (SeCys) was 
obtained by incubating seleno-l-cystine with three equivalents of DTT for 30 min at 37 °C. The 
final concentration of the gold compounds was 50 μM during incubations. The aliquots were 
diluted (1 + 9 v/v) with MeOH before injection into the mass spectrometer. The entire set of 
experiments was carried out in purely aqueous and in buffered solution (ammonium carbonate, 
20 mM, pH 7.4). 
Samples were analysed on a Synapt G2-Si time-of-flight (TOF) mass spectrometer (Waters) by 
direct infusion (DI) at an infusion rate of 3 μL·min-1 and averaged over 0.5 min. Mass spectra 
were acquired and processed using MassLynx V4.1 (Waters). The instrumental parameters 
were as follows: 2.5–3.5 kV capillary voltage, 120 °C source temperature, 180 °C  desolvation 
temperature, 90 L·h-1 cone gas, 480–720 L·h-1 desolvation gas and 6 bar nebulizer. 
 
FRET melting assays 
 32 
FRET experiment were performed in 96-well plates and run on an Applied Biosystems® 
QuantumStudio5 Real-Time PCR cycler equipped with a FAM filter (λex = 492 nm; λem = 516 
nm). Fluorolabelled 21-mer hTelo oligonucleotide, d[GGG(TTAGGG)3], was purchased from 
Eurogentec (Belgium) in HPLC purity grade. The FRET probes used were FAM (6-
carboxyfluorescein) and TAMRA (6-carboxy-tetramethylrhodamine). The lyophilized strands 
were firstly diluted in MilliQ water to obtain 100 μM stock solutions. Stock solutions were 
diluted to a concentration of 400 nM in 60 mM potassium cacodylate buffer (pH 7.4) and then 
annealed to form G4 structures by heating to 95 °C for 5 min, followed by slowly cooling to 
room temperature overnight. 
Experiments were carried out in a 96 well plate with a total volume of 30 μl. Final concentration 
of the oligonucleotide was 200 nM. All gold compounds were previously dissolved in DMSO 
to give 1 mM stock solutions, which were further diluted using 60 mM potassium cacodylate, 
and added to the wells to obtain a final concentration of 1 μM (with a total percentage of DMSO 
ca. 0.1%). The machine was set to perform a stepwise increase of 0.3 °C every 30 s starting 
from 25 °C to reach 95 °C, and measurements were acquired after each step. To compare 
different sets of data, FAM emission was normalised (0 to 1). T1/2 is defined as the temperature 
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Table of Contents Synopsis.  
The synthesis of novel hydrophilic gold(I) NHC complexes is reported. Selected compounds 
distinctly target the pivotal biological target thioredoxin reductase (TrxR) in the nanomolar 
range as benchmark anticancer drug auranofin, and exhibit remarkable antiproliferative effects 
against human ovarian cancer cells. 
 
 
 
 
 
 
